Skystar Bio-Pharmaceutical Company news

   Watch this stock
Showing stories 1 - 10 of about 13   

Articles published

SKBI 5.72 +0.21 (3.81%)
price chart
Skystar Bio Pharmaceutical Company: Undervalued With A Strong Growth Catalyst
Skystar Bio Pharmaceutical Company (SKBI) represents an interesting potential investment opportunity. The company provides niche products for China's animal husbandry industry.
Related articles »  
Skystar Bio-Pharmaceutical's Management Discusses Q4 2013 Results ...
Greetings and welcome to the Skystar Bio-Pharmaceutical Reports Fiscal 2013 Results Call. At this time, all participants are in listen-only mode.
Related articles »  
Skystar Bio-Pharmaceutical Reports Fiscal Year 2013 Financial Results and ...
XI'AN, CHINA--(Marketwired - Mar 31, 2014) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today ...
Related articles »  
Skystar Bio-Pharmaceutical Provides Update to Its Patent Portfolio
Commenting on these developments, Mr. Weibing Lu, Chairman and CEO of the Company, said, "We are pleased to have received patent protection from China's SIPO for these two products.
Related articles »  
Healthcare New Highs: UnitedHealth Group Inc. (NYSE:UNH), WellPoint Inc ...
The Board of Directors (the �Board�) of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) approved and the Company entered into a five-year employment agreement with Weibing Lu, the Company's current Chairman of the Board and CEO (the ...
Healthcare Losers: The Medicines Company (NASDAQ:MDCO), Galectin ...
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, on 31 march announced full financial results for fiscal year ended December 31, 2013.
Related articles »  
Drug Most Volatile Stocks: TherapeuticsMD (NYSEMKT:TXMD), Retrophin ...
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, on 31 march announced full financial results for fiscal year ended December 31, 2013.
Adherex At ASCO, FDA Panel Backs CBST, DRTX, PRAN's IMAGINE Fails, SKBI ...
According to the company, in the imaging trial, dubbed IMAGINE, PBT2 did not produce a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients.
Related articles »  
Skystar Bio Pharmaceutical Co gives FY 2014 revenue guidance